Introduction
There are conflicting data on the relation between high serum cholesterol levels and ischaemic stroke [1, 2] . During the last 20 years, a plethora of epidemiological studies suggest a close relationship [3, 4] and a metaanalysis of 14 randomized studies with 90 056 participants showed that every 38 mg/dl (1.0 mmol/l) reduction in lowdensity lipoprotein cholesterol (LDL-C) reduces the risk for all strokes by 17% [5] . However, it has also been suggested that there is an inverse association between serum cholesterol levels and the incidence of intracerebral haemorrhage [6] . This was first reported in the Multiple Risk Factor Intervention Trial (MRFIT) [7] , which showed that the risk of death from ischaemic stroke increased in proportion to serum cholesterol in 351 000 US men of age 35-57 years, but reported a negative association of low serum cholesterol levels and haemorrhagic stroke (particularly among patients with higher blood pressure) [7] . In patients with serum cholesterol concentrations less than 200 mg/dl (5.2 mmol/l), the lower the total cholesterol levels, the greater the risk of haemorrhagic stroke, suggesting a U-shaped relationship between cholesterol concentration and total stroke risk [7] . Furthermore, a recent study in a Japanese population reported a significant association between low LDL-C levels and increased risk of death due to intracerebral haemorrhage [8] . Similar reports suggested that Chinese [9] [10] [11] and other Asian populations [12] have an increased propensity to haemorrhagic stroke related to low LDL-C levels. However, not all epidemiological studies confirmed this relation [13] . The Korean Medical Insurance Corporation Study evaluated 114 793 Korean men (mean age of 45 years) over a 6-year period [14] . Low serum cholesterol was not associated with increased risk for intracerebral or subarachnoid haemorrhage [14] . In contrast, the Honolulu Heart Program (HHP) [15] , which evaluated 7850 men of Japanese-American descent over 18 years, reported a significant inverse correlation between serum cholesterol levels and the risk for intracerebral but not subarachnoid haemorrhage. The relation was nonlinear, with a higher incidence only in men whose Purpose of review To assess the potential association between haemorrhagic stroke and achieving very low serum cholesterol levels with aggressive statin treatment.
Recent findings
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study showed a reduction in both fatal and nonfatal stroke but an increase in the risk for haemorrhagic stroke during high-dose atorvastatin treatment. However, post-hoc analyses of this trial showed that this increased risk is primarily observed in elderly men with a history of haemorrhagic stroke. In addition, there was no relationship between baseline or on-treatment low-density lipoprotein cholesterol (LDL-C) levels and haemorrhagic stroke. Summary Existing data suggest that low LDL-C levels during intensive statin treatment are not associated with an increased risk for haemorrhagic stroke, except in patients with a history of intracerebral haemorrhage. In patients with a history of ischaemic stroke, intensive statin treatment substantially reduces the risk for both recurrent ischaemic stroke and for coronary heart disease (CHD) events. Any possible excess of haemorrhagic stroke is greatly outweighed by the protective effect against ischaemic stroke and CHD events. serum cholesterol levels were in the lowest quintile (<189 mg/dl; 4.9 mmol/l) [15] .
Keywords
Haemorrhagic stroke might be associated with low socioeconomic status. Very low income appears to be related more with haemorrhagic strokes than with coronary heart disease (CHD). During the last decades of economic growth, an epidemiological transition occurred from haemorrhagic to ischaemic stroke and CHD [9, 16] . Another issue is whether reduction in serum cholesterol with aggressive hypolipidaemic treatment has a similar association with haemorrhagic stroke as naturally occurring low serum cholesterol levels [17 ] .
Methods
A literature search (using PubMed) was performed using the following keywords: 'low LDL-C levels', 'stroke', 'haemorrhagic stroke', 'intracerebral haemorrhage', 'subarachnoid haemorrhage', 'intensive statin treatment' and 'safety' up to 9 February 2010. Reference lists of the retrieved articles, review articles, guidelines from scientific societies and randomized controlled studies with statins were also scrutinized. A MEDLINE search was also performed to identify studies, metaanalyses and review articles that addressed outcomes during statin treatment in specific subgroups, for example patients with acute coronary syndromes (ACS) or stable CHD.
Hypolipidaemic drug treatment and haemorrhagic stroke
A meta-analysis that included data from both statin and nonstatin trials (diet or other hypolipidaemic agents) included 254 512 patients (946 582 person-years of exposure); nonstatin trials included 106 216 patients [17 ] . The odds ratio (OR) for the incidence of stroke in actively treated patients vs. controls was 0.88 [95% confidence interval (CI) 0.83-0.94, P < 0.001]. There was a significant relationship between percentage reduction in total cholesterol and LDL-C and percentage reduction in total strokes (P ¼ 0.0017), with each 1% reduction in total cholesterol predicting a 0.8% reduction in the risk of stroke. This effect was mainly driven by statin treatment. The benefit of nonstatin interventions was smaller than that of statins (test for heterogeneity vs. statins, P < 0.05) and not significant (diet, OR 0.92; fibrates, OR 0.98; other treatments, OR 0.81) [17 ] . In contrast, statins decreased the risk for total stroke (OR 0.85, 95% CI 0.78-0.92, P < 0.001) and stroke risk reduction was proportional to the percentage reduction in total cholesterol and LDL-C levels. There was no significant association between stroke reduction and changes in high-density lipoprotein cholesterol (HDL-C) levels and inconsistent associations with the reduction in triglyceride levels [17 ] .
Aggressive statin treatment and haemorrhagic stroke
Cholesterol is an essential component of cell membranes [18] . Cholesterol also appears to be important for maintaining the integrity of small cerebral vessels [18] . In addition to the reduction in cholesterol levels, statins might decrease platelet aggregation [19] and have other antithrombotic actions [20, 21 ] . This may potentially increase the risk of haemorrhage [19] .
In the randomized, placebo-controlled Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial [22] in 3086 patients with ACS [acute coronary syndrome (ACS), i.e. unstable angina or non-Qwave myocardial infarction (MI)], the primary endpoint (a composite of death, nonfatal MI, resuscitated cardiac arrest or recurrent symptomatic myocardial ischaemia) was reduced by 16% with aggressive statin treatment (atorvastatin 80 mg/day) compared with placebo (P ¼ 0.048). The effect of intensive cholesterol lowering with atorvastatin on the incidence of nonfatal stroke was a secondary endpoint of the MIRACL trial [17 ] . The incidence of nonfatal stroke and that of fatal plus nonfatal stroke were analysed by time to first occurrence during the 16-week follow-up period. Among 38 events adjudicated as fatal or nonfatal strokes, three were classified as haemorrhagic, one as embolic and 29 as thrombotic or embolic; five were of unidentified cause. Nonfatal stroke occurred in nine patients in the atorvastatin group and in 22 in the placebo group [relative risk (RR) 0.40, 95% CI 0.19-0.88, P ¼ 0.02]. Fatal or nonfatal stroke occurred in 12 and 24 patients treated with atorvastatin and placebo, respectively (RR 0.49, 95% CI 0.24-0.98, P ¼ 0.04) [22] . All three haemorrhagic strokes occurred in the placebo group [22] . In the atorvastatin group, mean LDL-C levels declined by 42% (from 124 to 72 mg/dl; 3.2 to 1.9 mmol/l) [23] and high-sensitivity C-reactive protein concentration (hsCRP) by 34% compared with placebo [24] (P < 0.0001 for both comparisons). However, the MIRACL trial was of short duration (16 weeks) and this period might have not been long enough to show any relation between intensive statin treatment and haemorrhagic stroke. Nevertheless, three haemorrhagic strokes did occur in the placebo group despite the relatively high LDL-C levels (125 mg/dl; 3.2 mmol/l) [23] .
The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial included 4162 patients with ACS and had a longer follow-up period (2 years). The results showed a reduction in the first occurrence of the primary endpoint (death, MI, stroke, unstable angina requiring hospitalization, revascularization occurring >30 days after the index ACS event and recurrent nonfatal events) by intensive lipid lowering with high-dose atorvastatin (80 mg/day) compared with moderate lipid lowering using standard-dose pravastatin (40 mg/day) [25 ] . Absolute numbers of patients who suffered a stroke were similar in the two groups (25 in the atorvastatin group and 21 in the pravastatin group; P ¼ 0.529) and there was no increase in haemorrhagic stroke in the atorvastatin group [25 ] . In addition, there was no significant relationship between achieved LDL-C levels and either total stroke or intracranial haemorrhage [26] . The PROVE IT-TIMI 22 trial was the first study to perform a head-to-head comparison of two different statin treatments (intensive vs. moderate) and provided comparative data on adverse event rates including stroke. Similar were the results of the A to Z trial [27] that included 4497 ACS patients. In A to Z, the early/intensive therapy arm received 40 mg simvastatin for 1 month and then 80 mg for the remainder of the trial; the delayed/ conservative (moderate) therapy arm received placebo for 4 months followed by 20 mg simvastatin for the remainder of the trial (20 months). During the entire study, the LDL-C levels in the intensive treatment group were below 70 mg/dl (1.8 mmol/l). There was no report for an increase in haemorrhagic stroke in the intensive treatment arm [27] .
The Treating to New Targets (TNT) trial [28] included 10 001 patients with stable CHD and LDL-C levels less than 130 mg/dl (3.4 mmol/l) who were randomized to double-blind therapy with atorvastatin 10 or 80 mg/day and were followed-up for a median of 4.9 years. The primary endpoint was the time to the first occurrence of a major cardiovascular event defined as CHD death, nonfatal nonprocedure-related MI, resuscitated cardiac arrest and fatal or nonfatal stroke. A consistent reduction in the rate of major cardiovascular events was observed with decreasing on-treatment LDL-C levels and the lowest event rate was recorded in patients with LDL-C less than 64 mg/dl (1.7 mmol/l). In addition, very low LDL-C levels were not associated with an increase in adverse events. The same applied in a subgroup of patients who achieved LDL-C levels less than 40 mg/dl (1.0 mmol/l). Analysis of haemorrhagic stroke rates demonstrated no significant trend across quintiles. In particular, no increase was observed at the lowest on-treatment LDL-C levels [incidence of haemorrhagic stroke 6 (0.3%), 5 (0.3%), 6 (0.3%), 8 (0.4%), 7 (0.4%) in patients with LDL-C levels <64, 64-77, 77-90, 90-106 and 106 mg/dl, respectively] (1.7, 1.7-2.0, 2.0-2.3, 2.3-2.7 and 2.7 mmol/l, respectively) [28] .
The Heart Protection Study (HPS) [29] involved 20 536 high-risk individuals (with MI or known CHD, noncoronary atherosclerosis, diabetes or hypertension) and compared simvastatin 40 mg/day with placebo for a 5-year period. Total cholesterol levels before randomization were 135 mg/dl (3.5 mmol/l) or more and the participants were not considered definite candidates for hypolipidaemic therapy based on available evidence at the time [29] . A post-hoc analysis [30] of a subgroup of 3280 patients who had had a previous stroke showed a 25% reduction in stroke [444 (4.3%) in the simvastatin group vs. 585 (5.7%) in the placebo group; 95% CI 15-34, P < 0.0001]. There was a 28% reduction in presumed ischaemic strokes (95% CI 19-37, P < 0.0001) and no apparent difference in haemorrhagic strokes [51 (0.5%) vs. 53 (0.5%) in the simvastatin and placebo groups, respectively; RR 0.95, 95% CI 0.65-1.40, P ¼ 0.8] [30] . These results suggest that treatment of high-risk patients with simvastatin 40 mg/day reduces the rate of ischaemic strokes by about 25%. HPS also provides evidence that statins are beneficial in patients with a history of cerebrovascular disease even in the absence of established CHD and that the risk of intracerebral haemorrhage is not increased even among individuals who achieve very low LDL-C levels [30] . In the entire HPS trial [29, 30] , lowering cholesterol did not increase the risk of haemorrhagic stroke even among the 6793 participants with pretreatment LDL-C concentration less than 115 mg/dl (3.0 mmol/l) who achieved on-treatment LDL-C levels approximately 70 mg/dl (1.8 mmol/l).
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study [31] compared (for a period of 4.9 years) atorvastatin 80 mg/day with placebo in 4731 patients with a history of stroke or transient ischaemic attack (TIA), but without CHD. LDL-C levels in the atorvastatin and placebo arms were 73 and 129 mg/dl (1.9 and 3.3 mmol/l), respectively, throughout the study. Atorvastatin reduced the adjusted RR for fatal or nonfatal stroke by 16% (P ¼ 0.03) and the RR for fatal stroke alone by 43% (P ¼ 0.03). Among the secondary endpoints, atorvastatin reduced the relative risks for stroke and TIA (by 23%, P < 0.001), TIA alone (by 26%, P ¼ 0.004) and ischaemic stroke (by 22%, P ¼ 0.01) [31] . However, there was an increased incidence of haemorrhagic stroke in the atorvastatin group vs. placebo [55 cases (2.3%) vs. 33 cases (1.4%), respectively; P ¼ 0.02]; none of the 55 haemorrhagic strokes was fatal. Nevertheless, the overall benefit of atorvastatin in terms of the reduction in the risk of stroke was significant despite the increase in haemorrhagic stroke. A post-hoc analysis of SPARCL [32] showed no relationship between baseline LDL-C or recent LDL-C levels and the risk of haemorrhagic stroke. Among the 4731 patients included in this trial, 67% had ischaemic strokes, 31% TIA and 2% haemorrhagic strokes as entry events. Cox multivariable regression analysis showed that the risk for haemorrhagic stroke was greater in patients treated with atorvastatin [hazard ratio (HR) 1.68, 95% CI 1.09-2.59, P ¼ 0.02)], in those with a haemorrhagic stroke as the entry event (HR 5.65, 95% CI 2.82-11.30, P < 0.001), in men (HR 1.79, 95% CI 1.13-2.84, P ¼ 0.01) and in older patients (HR 1.42 for every 10-year increase in age, 95% CI 1.16-1.74, P < 0.001). There were no statistical interactions between treatment and other predisposing factors for haemorrhagic stroke. Multivariable analyses also showed that having stage 2 hypertension at the last study visit before the haemorrhagic stroke increased the risk (HR 6.19, 95% CI 1.47-26.11, P ¼ 0.01), but there was no association between most recent LDL-C level and the risk for haemorrhagic stroke in the atorvastatin group [32] . This post-hoc analysis of SPARCL showed that, in addition to treatment with atorvastatin, having haemorrhagic stroke as an entry event, being male and elderly at baseline accounted for 86% of the increased risk for haemorrhagic stroke [32] . When making therapeutic decisions, the increase in the risk of haemorrhagic stroke observed in SPARCL, if it is not due to chance, must be balanced against the benefit of atorvastatin treatment in reducing the risk of total stroke and other vascular events. Indeed, although patients had no known CHD at baseline, the risk for CHD events, including major (RR 0.65, 95% CI 0.49-0.87, P ¼ 0.003) and any CHD event (RR 0.58, 95% CI 0.46-0.73, P < 0.001), was significantly reduced by atorvastatin [31] . A further analysis of SPARCL has suggested that statins reduce the severity of stroke as measured using the Rankin scale and increase the proportion of event-free individuals with no difference between subgroups including secondary haemorrhagic strokes [33] .
In the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), of 17 802 at moderate cardiovascular risk, with LDL-C levels less than 130 mg/dl (3.36 mmol/l) and CRP more than 2.0 mg/l, rosuvastatin 20 mg produced a 52% reduction in LDL-C. After a median follow-up of 1.9 years (maximum, 5.0 years), statin therapy reduced fatal and nonfatal stroke by 48% (RR 0.52, 95% CI 0.34-0.79, P ¼ 0.002). This finding was due to a 51% reduction in the rate of ischaemic stroke (RR 0.49, 95% CI 0.30-0.81, P ¼ 0.004), with no difference in the rates of hemorrhagic stroke (RR 0.67, 95% CI 0.24-1.88, P ¼ 0.44). Thus, in primary prevention, no excess of haemorrhagic stroke is seen even with aggressive LDL-C reduction [34 ] .
Conclusion
Existing data suggest that low LDL-C levels during intensive statin treatment are not associated with an increased risk for haemorrhagic stroke, except for patients with a history of intracerebral haemorrhage. However, the mean duration of follow-up in statin trials has been relatively short (<5 years) [35] . It is unclear whether longer exposure to low LDL-C levels alters the integrity of small cerebral vessels and this might become a clinically significant issue if aggressive LDL-C lowering is sustained over prolonged periods [18] . This might be particularly relevant for Asians, a population at higher risk for intracerebral haemorrhage [12, 15, 18, 19] .
In the SPARCL trial, statin benefit was independent of baseline LDL-C and other lipid levels [36, 37, 38 ] . These findings extend the results of HPS [30] and the metaanalysis of randomized trials with statins [5] by showing a benefit of statin treatment in patients with a recent stroke or TIA but no known CHD. Accordingly, patients with stroke or TIA might have to receive high-dose statin treatment regardless of their LDL-C levels. Moreover, the risk for CHD is substantial in these patients and exceeds the risk for recurrent stroke [38 ] . Existing evidence suggests that intensive statin treatment, by achieving low LDL-C levels, substantially reduces CHD events (by almost 50%) and total stroke (by 17%), mainly through the prevention of nonfatal strokes with little effect on the risk of fatal stroke. Any possible excess of haemorrhagic stroke is outweighed by the protective effect against CHD events and ischaemic stroke.
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